Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)
 
 • Company Description   
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

Number of Employees: 392

 
 • Price / Volume Information   
Yesterday's Closing Price: $21.10 Daily Weekly Monthly
20 Day Moving Average: 698,001 shares
Shares Outstanding: 54.79 (millions)
Market Capitalization: $1,156.05 (millions)
Beta: 1.51
52 Week High: $62.16
52 Week Low: $19.97
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.33% -4.64%
12 Week -27.57% -20.37%
Year To Date -35.81% -23.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
88 SIDNEY STREET
-
CAMBRIDGE,MA 02139
USA
ph: 617-649-8600
fax: -
investors@agios.com http://www.agios.com
 
 • General Corporate Information   
Officers
Jacqualyn A. Fouse - ChiefExecutiveOfficerand Director
Jonathan Biller - Chief Financial Officer and Head of Corporate Affa
Paul J. Clancy - Director
Ian Clark - Director
Kaye Foster - Director

Peer Information
Agios Pharmaceuticals, Inc. (BJCT)
Agios Pharmaceuticals, Inc. (CADMQ)
Agios Pharmaceuticals, Inc. (APNO)
Agios Pharmaceuticals, Inc. (UPDC)
Agios Pharmaceuticals, Inc. (IMTIQ)
Agios Pharmaceuticals, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 00847X104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 54.79
Most Recent Split Date: (:1)
Beta: 1.51
Market Capitalization: $1,156.05 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.78 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-7.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 7.33% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.96
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -32.82%
vs. Previous Quarter: 3.87%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -25.67
12/31/21 - -21.27
09/30/21 - -24.47
ROA
03/31/22 - -23.29
12/31/21 - -19.42
09/30/21 - -21.05
Current Ratio
03/31/22 - 21.30
12/31/21 - 17.79
09/30/21 - 22.55
Quick Ratio
03/31/22 - 21.24
12/31/21 - 17.79
09/30/21 - 22.55
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -43,318.15
12/31/21 - -
09/30/21 - -777.54
Book Value
03/31/22 - 22.04
12/31/21 - 23.79
09/30/21 - 25.68
Inventory Turnover
03/31/22 - 0.55
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.02
12/31/21 - 0.02
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©